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Short QT syndrome (SQTS) is a rare hereditary disease that
predisposes to life-threatening arrhythmias.1 Prophylactic
therapy with hydroquinidine (HQ) has been shown to
prolong the QT interval in patients with the p.N588K
mutation in the KCNH2 gene2,3 and reduce the occurrence
of ventricular arrhythmias in a long-term follow-up, regard-
less of genotype.4 In vitro analyses have suggested a possible
role for sotalol in the prophylactic treatment of patients with
a different mutation (p.T618I) in the KCNH2 gene.5 We
report 3 patients from a single family with SQTS thought to
be due to the p.T618I-KCNH2mutation and detail the effects
of HQ and sotalol treatment in these patients.
Case report
A 16-year-old male patient (patient 1) was referred to our
institution after the detection of a short QT interval and
frequent ventricular ectopic beats on an electrocardiogram
(ECG). He had no history of symptoms suggesting arrhyth-
mias or heart failure. His resting ECG showed a QT interval of
260 milliseconds at a heart rate (HR) of 80 beats per minute,
corrected QT (QTc) 300 milliseconds, with tall and peaked T
waves in the precordial leads and asymmetric negative T
waves in the inferior leads (Figure 1A). Echocardiography
results showed a dilated and slightly hypokinetic left ventricle,
ejection fraction 48%. Cardiac magnetic resonance excluded
myocarditis. Before the patient came to our institution, lamin
A/C gene analysis had been performed to exclude a familialKEYWORDS Drug therapy; Genetics; Hydroquinidine; Polymorphisms; Short
QT syndrome; Sotalol; Sudden death
ABBREVIATIONS EPS ¼ electrophysiological study; HQ ¼ hydroqui-
nidine; HR ¼ heart rate; nsVT ¼ nonsustained ventricular tachycardia;
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hour ECG recording showed a QT interval always below the
lower limits. Frequent isolated ventricular beats representing
12% of the total heartbeats with coupling intervals of 375–460
milliseconds and occasional bigeminy were recorded. The
ectopy occurred mostly at night. There was no ventricular
tachycardia. Stress test results revealed a poor shortening of
the QT interval with HR increase,6 with an absolute QT value
ranging from 240 milliseconds at rest (HR 75 beats per
minute) to 200 milliseconds at peak effort (HR 194 beats per
minute); no arrhythmias were recorded. An electrophysiolog-
ical study (EPS) was performed and showed very short atrial
and ventricular refractory periods (atrial 130 milliseconds;
right ventricular apex 160 milliseconds and right ventricular
outflow tract 150 milliseconds at a cycle length of 600
milliseconds); no ventricular arrhythmias were induced with
programmed stimulation.
The patient’s family history (Supplement 1) included
several unexplained sudden deaths. The patient’s mother had
died at the age of 34 during sleep; her ECG showed a QT
interval of 270 milliseconds (QTc 300 milliseconds). The
proband’s maternal great grandfather had died at the age of
40 shortly after awakening, and a maternal second-degree
cousin had died suddenly at the age of 33 at home (no ECGs
available).
The asymptomatic 21-year-old sister of the index case
(patient 2) had an ECG with a QT interval of 280 milli-
seconds and a QTc of 340 milliseconds (Figure 2A). Her
echocardiogram was unremarkable. Poor adaptation of QT
interval at different HRs was observed during 24-hour ECG
recordings and exercise test; no arrhythmias were recorded.
Short atrial and ventricular refractory periods were recorded
during an EPS, and no arrhythmias were induced.
These 2 siblings with ECG evidence of short QT
intervals and a family history of sudden death in a first-
degree relative fit the diagnosis of SQTS. The ventricular
ectopy in the proband was of concern. Thus, 2 manage-
ment strategies were considered: the implantation of anpen access article under the CC BY-NC-ND license
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KEY TEACHING POINTS
 Short QT syndrome is an inherited channelopathy
that predisposes patients to life-threatening
arrhythmias. Most patients who have been
genotyped carry a mutation in the KCNH2 gene.
An implantable cardioverter-defibrillator is the
treatment of choice in individuals who have
experienced cardiac arrest or syncope.
 Clinical studies on a limited number of subjects
have demonstrated the efficacy of long-term
prophylactic treatment with hydroquinidine in
prolonging the QT interval and preventing atrial
and ventricular arrhythmias in both symptomatic
and asymptomatic SQTS patients, regardless of
their genotype. Other antiarrhythmic drugs,
including flecainide, sotalol, and ibutilide, have
been tried in patients with the KCNH2-N588K
mutation and did not show any efficacy.
 An in vitro study suggested a possible role for
pharmacologic therapy with sotalol in SQTS
patients with the KCNH2-T618I mutation. In this
first in vivo report, this drug did not prove to be
effective. Further evidence is needed before its use
in the setting of SQTS can be recommended.
Heart Rhythm Case Reports, Vol 1, No 5, September 2015374implantable cardioverter-defibrillator or a pharmacologic
prophylaxis with HQ. Because of their youth and the
absence of symptoms and of induced arrhythmias during
EPS, both patients were started on 250 mg of HQ twice
daily.
At his 6-month outpatient visit, the ECG of patient 1
showed a QT of 340 milliseconds at an HR of 60 beats per
minute (QTc 340 milliseconds), with HQ serum levels at the
lower limits (0.6 μg/mL; therapeutic range 0.6–2.2 μg/mL),
although his HQ dosage had already been increased to 250
mg 3 times daily, so HQ dosage was further increased to 500
mg twice daily. At 6 months, the ECG of patient 2 showed a
QT of 320 milliseconds and a QTc of 376 milliseconds, but
her HQ serum levels were very low (0.280 μg/mL), and thus
her HQ dosage was increased to 250 mg 3 times daily.
Both patients underwent implantation of a loop recorder
to closely monitor for arrhythmias. At their 12-month
follow-up visits, the devices had recorded no arrhythmias.
The QT interval remained very short in patient 1 (QT 320
milliseconds, QTc 333 milliseconds) (Figure 1B), despite
HQ serum level was in the therapeutic range (0.907 μ g/mL).
In patient 2 the QTc interval had increased to 389 milli-
seconds with HQ 250 mg 3 times daily (HQ serum level
0.983 μg/mL, Figure 2B).
A 47-year-old maternal aunt of the 2 siblings (patient 3)
(Supplement 1) experienced a sudden loss of consciousness
in a public office. She was promptly resuscitated. Her heartrhythm at the time of arrest was ventricular fibrillation,
which was successfully terminated via external defibrillation
by emergency medical personnel. The first available ECG on
sinus rhythm showed QT and QTc intervals of 260 and 355
milliseconds, respectively, with peaked T waves in the
precordial leads. Coronary angiogram, echocardiogram, and
magnetic resonance results were normal. A subsequent ECG
confirmed the short QT intervals (QT 300 milliseconds,
QTc 344 milliseconds at an HR of 79 beats per minute)
(Figure 3A). An implantable cardioverter-defibrillator was
implanted and therapy with 250 mg of HQ twice daily
started. At her 4 month follow-up, the QT and QTc values
were unchanged, and the device had recorded 4 episodes of
nonsustained ventricular tachycardia (nsVT) up to 3 seconds
in duration with subtherapeutic HQ levels (0.552 μg/mL)
(Supplement 2A).
After we obtained written informed consent, a genetic
analysis of KCNQ1 and KCNH2 genes was performed. All 3
patients were found to have in heterozygosis the C to T
transition at nucleotide 1853 (c.1853C4T) in the KCNH2
gene, which results in the change of the amino acid threonine
to isoleucine at position 618 (p.T618I). Patient 1 was also
found to have in homozygosis the KCNH2 polymorphism
p.K897T, whereas patients 2 and 3 demonstrated this poly-
morphism in heterozygosis.
Because of the poor effect of HQ in prolonging the QT
interval in patients 1 and 3, and in preventing ventricular
arrhythmias in patient 3, we decided to evaluate the effect of
sotalol in these 2 subjects. They started therapy at the dosage
of 40 mg 3 times daily, which was increased after 5 days to 80
mg twice daily because no effect on QT interval was noticed.
An ECG performed 10 days later in patient 1 continued to
show ventricular bigeminy and a QT interval of 280 milli-
seconds (Figure 1C). Patient 3 had initial QT and QTc values
of 340 milliseconds and similar values after increasing the
sotalol dosage up to 80 mg 3 times daily (QT 330, QTc 343
milliseconds) (Figure 3B). We stopped sotalol and restarted
HQ in both patients, 500 mg twice daily in patient 1 and 250
mg 3 times daily in patient 3. Two weeks later, patient 3 ECG
showed an increase of the QT interval to 360 milliseconds and
of the QTc to 411 milliseconds (Figure 3C).
During a mean follow-up of 59 14 months, none of the
patients complained of any symptom. Patient 1 still showed
QTc values below the normal limits, but with HQ therapy,
ventricular ectopy had been suppressed. Patient 2 had a slow
nsVT recorded by the loop recorder (Supplement 2B), and
patient 3 continued to have runs of nsVT but at slower rates
than before (Supplement 2C).Discussion
This article gives the first report of the in vivo effects of
sotalol in SQTS patients carrying the p.T618I mutation in the
KCNH2 gene. Our data do not suggest a clinical efficacy in
these patients, neither in prolonging the QT interval to
normal values nor in preventing ventricular arrhythmias.
Figure 1 Patient 1. A: Baseline electrocardiogram (ECG) results: heart rate (HR) 80 beats per minute, QT 260 milliseconds, corrected QT (QTc) 300
milliseconds. B: ECG recorded during treatment with 500 mg of HQ twice daily: HR 65 beats per minute, QT 320 milliseconds, QTc 333 milliseconds. C: ECG
recorded during treatment with 80 mg of sotalol twice daily: bigeminy, QT interval 280 milliseconds.
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Figure 2 Patient 2. A: Baseline ECG: HR 88 beats per minute, QT 280 milliseconds, QTc 340 milliseconds. B: ECG recorded during treatment with 250 mg
of HQ 3 times daily: HR 70 beats per minute, QT 360 milliseconds, QTc 389 milliseconds. Abbreviations as in Figure 1.
Heart Rhythm Case Reports, Vol 1, No 5, September 2015376Our group first evaluated the clinical effect of various
antiarrhythmic drugs, including flecainide, sotalol, ibutilide,
and HQ, in 2 SQTS families carrying the p.N588K mutation
in the KCNH2 gene,3 and we found that HQ was effective both
in prolonging QT interval and ventricular effective refractory
periods, and in abolishing the inducibility of ventricular arrhyth-
mias during EPS. The p.N588K mutation was later shown to be
responsible for a 5.8-fold decrease in the IKr channel blocking
effect of HQ, in contrast to the 20-fold decrease in the effect of
sotalol.7 Later, we confirmed the long-term antiarrhythmic
efficacy of HQ, despite the fact that a reduced and less
homogeneous lengthening of the QTc was recorded in patients
with mutations other than the p.N588K in the KCNH2 gene.3,4
Other drugs, such as dysopiramide8 and amiodarone,4 have been
tested in a few subjects. The data for these alternate drugs are
limited and the drugs’ efficacy uncertain.
The p.T618I mutation in the pore loop of KCNH2
was described in a Chinese family with a history of sudden
death.5 In vitro analysis showed a smaller loss of theinhibitory effect of sotalol on HERG channels compared
with that of the p.N588K mutation. However, in this study,
the sotalol concentration was 500 μM, whereas plasma
concentrations during long-term oral therapy generally range
from 1 to 3 mg/mL (88.4–265.2 μM/L).9 This difference may
in part explain the drug’s lack of effectiveness in our
patients. In the 2013 HRS/EHRA/APHRS expert consensus
statement on the diagnosis and management of patients with
inherited primary arrhythmia syndromes,10 the authors state
that sotalol may be considered in asymptomatic patients
with a diagnosis of SQTS and a family history of sudden
cardiac death.
Genetic analysis of the family in our study showed, in
addition to the p.T618I mutation, the presence of the
p.K897T polymorphism in KCNH2. It is well known
that in the general population genetic variants have been
associated with the variability of the QT interval.11 Although
the p.K897T polymorphism has been widely investigated,
there is no agreement on its effect on repolarization.12–14
Figure 3 Patient 3. A: Baseline ECG: HR 79 beats per minute, QT 300 milliseconds, QTc 344 milliseconds. B: ECG recorded during treatment with 80 mg of
sotalol 3 times daily: HR 65 beats per minute, QT 330 milliseconds, QTc 343 milliseconds.C: ECG recorded during treatment with 250 mg of HQ 3 times daily:
HR 78 beats per minute, QT 360 milliseconds, QTc 411 milliseconds. Abbreviations as in Figure 1.
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Heart Rhythm Case Reports, Vol 1, No 5, September 2015378The presence of genetic modifiers of repolarization may in
part explain the familial phenotypic differences and different
responses to medications seen in SQTS cases. The reduced
efficacy of HQ in patient 1 may be related to his homozygous
expression of the p.K897T polymorphism, in contrast to the
heterozygous expression in patients 2 and 3. The homozygous
expression may confer greater influence on the QT length.
Also, after increasing the HQ dosage and with adequate HQ
plasma levels, patient 1 still showed a short QT interval;
however, he remained asymptomatic and his ventricular ectopy
resolved, suggesting that the efficacy of HQ does not rely only
on QT prolongation. Left ventricular function, however, did not
vary. We observed in some SQTS patients a reduced ejection
fraction and a higher mechanical dispersion of contraction
compared with those of controls15; our hypothesis is that
accelerated repolarization might result in altered calcium
loading and therefore in a reduction in contractile activity.
Further studies are needed to evaluate the efficacy of a
genotype-guided pharmacologic therapy for SQTS patients.
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